Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques

Sandra M. Penz; Armin J. Reininger; Orsolya Toth; Hans Deckmyn; Richard Brandi; Wolfgang Siess

doi:10.1160/TH06-07-0415

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(03): 435-443
DOI: 10.1160/TH06-07-0415

Platelets and Blood Cells

Schattauer GmbH

Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques

Sandra M. Penz

¹Institute for Prevention of Cardiovascular Diseases, University of Munich, Munich, Germany

,

Armin J. Reininger

²Department of Transfusion Medicine and Hemostaseology, University of Munich, Munich, Germany

,

Orsolya Toth

¹Institute for Prevention of Cardiovascular Diseases, University of Munich, Munich, Germany

³1^stDepartment of Medicine, University of Pécs, Pécs, Hungary

,

Hans Deckmyn

⁴Laboratory for Thrombosis Research, IRC, KU Leuven Campus Kortrijk, Kortrijk, Belgium

,

Richard Brandi

⁵Department of Vascular Surgery, Klinikum Munich-Schwabing, Munich, Germany

,

Wolfgang Siess

¹Institute for Prevention of Cardiovascular Diseases, University of Munich, Munich, Germany

› Author Affiliations

Abstract

Summary

Anti-platelet drugs are used to prevent intra-arterial thrombus formation after rupture of atherosclerotic plaques. Until now, the inhibitory effect of present and future anti-platelet drugs such as aspirin, ADP receptor P2Y₁/P2Y₁₂ antagonists and glycoprotein (GP) Ibα inhibitors on the interaction of platelets with human plaques is not known. To study those effects we obtained human atherosclerotic plaques by surgical endarterectomy. Plaques induced maximal platelet aggregation in hirudinized platelet-rich plasma (PRP) and blood that was effectively inhibited by aspirin, the P2Y₁ antagonist MRS2179 and the P2Y₁₂ antagonist AR-C69931 MX, but not by GPIbα blockade with the mAB 6B4. Inhibition of platelet aggregation by MRS2179 was 74 ± 37% and 68 ± 20%, by AR-C69931 MX 94 ± 7% and 80 ± 6%, and by aspirin 88 ± 19% and 64 ± 28%, in PRP and blood, respectively (mean ± SD; n6–12 with plaques from 6 patients). The combination of both ADP receptor antagonists completely inhibited plaque-induced platelet aggregation in hirudinized PRP and blood. Under arterial flow conditions (1,500s^-1), blockade of platelet GPIbα– resulted in a strong decrease of plaque-stimulated platelet adhesion/aggregate formation of 77 ± 5% (mean ± SD; n=4). Furthermore, MRS2I79, AR-C6993IMX and their combination reduced plaque-dependent platelet aggregate formation by 35 ± 14%, 32 ± 13% and 58 ± 12% (mean ± SD; n=5), respectively. Aspirin was without significant effect. In conclusion, a GPIbα-blocking antibody, as well as P2Y₁ and P2Y₁₂ receptor antagonists, alone or in combination, reduce in contrast to aspirin human plaque-induced platelet thrombus formation under arterial flow. Although these new anti-platelet agents inhibit platelet thrombus formation after plaque rupture, more efficient platelet blockers are required.

Keywords

ADP receptor antagonists - aspirin - GPIb - plaque - platelet throm bus formation

Full Text

References

References
1 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
2 Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 2002; 113: 668-680.
3 Fernandez-Ortiz A, Badimon JJ, Falk E. et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
4 van Zanten GH, de Graaf S, Slootweg PJ. et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615-632.
5 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
6 Siess W, Zangl KJ, Essler M. et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999; 96: 6931-6936.
7 Rother E, Brandl R, Baker DL. et al. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003; 108: 741-747.
8 Penz S, Reininger AJ, Brandl R. et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19: 898-909.
9 Guyton JR, Klemp KF. Development of the lipidrich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4-11.
10 Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274.
11 De Meyer GR, Hoylaerts MF, Kockx MM. et al. Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 1999; 19: 2524-2534.
12 Barnes MJ, Farndale RW. Collagens and atherosclerosis. Exp Gerontol 1999; 34: 513-525.
13 Abi-Younes S, Sauty A, Mach F. et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131-138.
14 Weidtmann A, Scheithe R, Hrboticky N. et al. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vasc Biol 1995; 15: 1131-1138.
15 Merten M, Dong JF, Lopez JA. et al. Cholesterol sulfate: a new adhesive molecule for platelets. Circulation 2001; 103: 2032-2034.
16 Haseruck N, Erl W, Pandey D. et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004; 103: 2585-2592.
17 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
18 Kariyazono H, Nakamura K, Arima J. et al. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood Coagul Fibrinolysis 2004; 15: 157-167.
19 Phillips DR, Conley PB, Sinha U. et al. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005; 3: 1577-1589.
20 Barstad RM, Orvim U, Hamers MJ. et al. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 1996; 75: 827-832.
21 Eikelboom JW, Hankey GJ. Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs 2004; 4: 57-67.
22 Hanson SR, Sakariassen KS. Blood flow and antithrombotic drug effects. Am Heart J 1998; 135: S132-145.
23 Cosemans JM, Kuijpers MJ, Lecut C. et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005; 181: 19-27.
24 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
25 Cauwenberghs N, Vanhoorelbeke K, Vauterin S. et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-660.
26 Brandl R, Richter T, Haug K. et al. Topographic analysis of proliferative activity in carotid endarterectomy specimens by immunocytochemical detection of the cell cycle-related antigen Ki-67. Circulation 1997; 96: 3360-3368.
27 Savi P, Bernat A, Lale A. et al. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist. Platelets 2000; 11: 43-48.
28 Cullen P, Baetta R, Bellosta S. et al. Rupture of the atherosclerotic plaque: Does a good animal model exist?. Arterioscler Thromb Vasc Biol 2003; 23: 529-534.
29 Schumacher KA, Classen HG, Spath M. Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb Haemost 1979; 42: 631-640.
30 Gerrard JM, Kindom SE, Peterson DA. et al. Lysophosphatidic acids. II. Interaction of the effects of adenosine diphosphate and lysophosphatidic acids in dog, rabbit, and human platelets. Am J Pathol 1979; 97: 531-547.
31 Tokamura A, Fukuzawa K, Isobe J. et al. Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. Biochem Biophys Res Commun 1981; 99: 391-398.
32 Belton OA, Duffy A, Toomey S. et al. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108: 3017-3023.
33 Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis 2006; 36: 206-210.
34 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
35 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
36 Sugimoto M, Tsuji S, Kuwahara M. et al. Shear-dependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on collagen surface. Int J Hematol 1999; 69: 48-53.
37 Maxwell MJ, Westein E, Nesbitt WS. et al. Identification of a two-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood. 2006 epub ahead of print
38 Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-178.
39 Ruggeri ZM, Orje JN, Habermann R. et al. Activation- independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-1910.
40 Kunapuli SP, Dorsam RT, Kim S. et al. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3: 175-180.
41 Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-3345.
42 Moake JL, Turner NA, Stathopoulos NA. et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: 1366-1374.
43 Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005; 108: 180-192.
44 Vilahur G, Segales E, Salas E. et al. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flowand lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004; 110: 1686-1693.
45 Remijn JA, Wu YP, Jeninga EH. et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686-691.
46 Goto S, Tamura N, Ishida H. et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006; 47: 155-162.
47 Goto S, Tamura N, Handa S. Effects of adenosine 5'-diphosphate (ADP) receptor blockade on platelet aggregation under flow. Blood 2002; 99: 4644-4645.